Dehydrodieugenol improved lung inflammation in an asthma model by inhibiting the STAT3/SOCS3 and MAPK pathways.

CONCLUSION: The obtained data demonstrate, for the first time, that dehydrodieugenol was more effective than eugenol in counteracting allergic airway inflammation in mice, especially its inhibition of the JNK, p38 and ERk1/2, components of MAPK pathway. Therefore, dehydrodieugenol can be considered a prototype for the development of new and effective agents for the treatment of asthmatic patients.
PMID: 32717226 [PubMed - as supplied by publisher]

Source: Biochemical Pharmacology - July 23, 2020 Category: Drugs & Pharmacology Authors: Santana FPR, Silva RCD, Ponci V, Pinheiro AJMCR, Olivo CR, Caperuto LC, Arantes-Costa FM, Claudio SR, Ribeiro DA, Tibério IFLC, Lima-Neto LG, Lago JHG, Prado CM Tags: Biochem Pharmacol Source Type: research